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Lung damage assessed by CT scan was  not predictive in 6 year-old 
CF children: a case conkol  study of a neonatal screened population 
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Recent reports enhanced the use of scored CT scan in early lung damage ha CF. A 
case control study was performed to assess the outcome at age 6y of a screened (S) 
compared to an unscreened (US) population, treated in two centres with similar 
pr ccedures. 
Respiratory and diges*d ve history of 33 S (Rouen) and 49 US infants (Toulouse) was 
collected, including PFgs and scored chest CT scan. A Bhal la modified score 
comprised of bronchial wal l  thickening (BWT), bronchiectasis, atelectasis, mucus 
plugs and air trapping (AT) evaluation was used (Robinson rITE, J Pediatr. 2C~)1 ).A 
normal score was 42. 
Cq" scan showed early mild lung damage in 81.8% patients in S and 81.6% ha US. 
Total mad detailed scores were similar in both groups. BWT was significantly more 
frequent han atelectasis, mucus plugging and AT (p<0.C~)l), and right upper lobe 
(RUL) significantly more affected than l ingula (p<0.C~)l). CT scan score was 
correlated with FEF25/75 in both groups. Extent mad severity of bronchiectasis ha 
all chi ldren were inversely correlated with BMI, FEV1, and FEF25F/5. No 
relationship was found between the onset or type of microbiological colonization, 
and the Cq" scan score or PFgs studied. 
Early diagnosis of CF did not appear to ilffluence the lung damage observed at age 
6, and no predictive factor was identified. Bronchiectasis was related to altered 
PFgs, nutritional status and signed a worsening disease. Early lung damage, 
correlated to the small airway disease mad BWT being the most widespread amage 
independently of colonization, might be the results of an early non specific 
inf lammation ha CF lung disease. 
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R117H-TT: clinical outcome of the newborns screened in Brittany with 
this variant 
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The clinical evolution of subjects compound heterozygous for a severe CFTR 
mutation and the R l l7H 7T remains unclear and it is difficult to provide a fully 
satisfactory genetic ounsell ing to the concerned families. In France, this constitutes 
a real matter as the R l l7H is detected by the kit used in the nationwide newborn 
screening (NS) program and appears the most frequent anomaly after the F508del 
(7.4%). The aim of this s*mdy was to describe the clinical outcome of the R117H 
compound heterozygotes screened ha Brittany (westem France) where a pilot 
experience of NS was set up ha 1989 mad where CF is frequent. Data on clinical 
status was obtained near the French CF Registry or directly near paediatricians. 
From 1989 to 2C~)4, 565 546 newborns were screened for CF in Brittany, among 
whom 195 had an elevated IRT and two CFTR mutations. N ine  of these children 
(4.6%) were compound heter ozygotes for the R l l7H,  which was ha all cases l inked 
to the 7T variant 0a508del /R l l7H (n~) ,  I507de l /R l l7H or G551D/Rl17H).  
Current mean age of these children is 5.7 y. [2.6 9.5]. Sweat chloride level, which 
was lower than 30 mEq/L ha four children, was in mean 37.7 mEq/L (~ 14.3). Al l  
the children are pancreatic sufficient. Their nutritional status and growth appear 
normal (height zcore: 0.5 (~ 1.0); weight zscore: c3.1 (~ 1.5)) and spirometric 
data, available for two children, are perfect (FVC: 117.5%; FEV1 : 109.4%). None 
of the children carrying a R l l7H 7T has yet developed signs of CF. As it has been 
reported that this al lele could be associated with some pulmonary symptoms, it is 
important o maintain their fol low up ha order to check the appearance of any 
clinical signs. 
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The effect of genotype on sweat test values 
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Baekgmmld:  The chal lenge for clinicians is to be able to exclude a diagnosis of CF 
and to identify atypical cases ha whom the diagnosis may have been missed. 
A ims:  To compare sweat est values in patients with CF according to the number of 
identified mutations and to describe the relationship between mutation class and 
sweat sodium and chloride values. 
Methods:  192 patients attended the Regional CF traits between 1 July 1994 and 30 
June 2CO4 for an assessment that included mutation analysis. 169 of these patients 
also had a sweat test performed. A total of 34 different mutations were identified 
with DF508 being the most common (gene frequency 63.5%). The mutation was 
tmlmown ha 9.3% of cbromosomes. 17 patients (8.9%) had normal or borderline 
sweat tests. The mild mutations R l17H,  Dl152,  3849+10kb(C>T) accounted for 
41% of CF genes in this group. 
Results:  Median (range) sweat sodium mad chloride concentrations were 91 
(15 141) and 98 (19 160) respectively for 2 identifiable mutations, 78.5 (49 116) 
and 86 (37 113) for 1 mutation and 103 (93 125) and 103 (95 140) ha the absence 
of any mutations. Sweat chloride results were borderline for 8 patients with two 
mutations and normal in tbree patients with two mutations mad one patient with a 
single mutation. A l l  patients with no CF mutations had unequivccal sweat test 
results. 
Normal sweat est results were associated with R117H 7T (n 3) and D 1152 + other. 
Conclusion: In a small minority of patients the diagnosis of CF remains a cl inical 
diagnosis and further electrophysiological tests are necessary. 
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Screening of defective cystic fibrosis (CF) genomes:  Two different 
approaches, one to be favored 
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According to some thought trends, heterozygote cmrier systematic screening 
(HCSS) could noticeably decrease, or even eradicate cystic fibrosis (CF) in 
populations. In a recent pas% there were two possible approaches, one adopted with 
macro populations (on the scale of a country or province, etc.), cal led "mass 
screening programs", the other with micro populations (nuclear or extended family, 
atMsk communities, etc.), called "cascade heter ozygote screening". 
A multidisciplinary analysis (clinician, geneticist, e hicist) submitted this double 
approach to the test of historical  experience and bioethics principles 
(beneficience/non maleficience, autonomy, justice and equity). 
(1) From a theoretical point of view, carrier screening in macro populations may 
appear commendable, but is in reality utopian for disease eradication: a) on the 
financial level, the cost/benefit ratio (diverse resources and infrastructures vs. 
population health) would be too high; (b) on the social and moral evel, laws should 
be passed and pressure put on people so that they accept o submit to HCSS. (2) 
Selective screening in micro populations is a more realistic approach: (a) small 
number of individuals or families included in a clinician/patient relationship; (b) 
greater respect of values, autonomy and equity; (c) better control of genetic 
information (job, insurance, etc.); (e) reduction of f inancial costs; (f) better access 
to health care, help and follow up in genetic ounselling. 
The conducted analysis shows that cascade heterozygote screening for CF is a 
method to be favored in view of screening experience mad ethical mad social values 
in a democratic society. 
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